A lean first quarter for venture-backed developers

Biopharma venture financings fell over each consecutive quarter last year, and that theme continued in the opening three months of 2023. The $3.3bn raised by private drug developers suggests that the sector could be heading back to 2017, when quarterly funding levels last dipped below $3bn.